Evaluation of Tofacitinib in Prevention of Photosensitivity in Lupus
Evaluation of Tofacitinib in Prevention of Photosensitivity in Cutaneous Lupus Erythematosus (ALE11)
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
This PHASE1 trial investigates Cutaneous Lupus and is currently completed. National Institute of Allergy and Infectious Diseases (NIAID) leads this study, which shows 12 recorded versions since 2022 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
12 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE1
-
Apr 2025 — Sep 2025 [monthly]
Completed PHASE1
-
Sep 2024 — Apr 2025 [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Apr 2024 — Jul 2024 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
▶ Show 7 earlier versions
-
Feb 2024 — Apr 2024 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Nov 2023 — Feb 2024 [monthly]
Recruiting PHASE1
-
Apr 2023 — Nov 2023 [monthly]
Recruiting PHASE1
-
Jun 2022 — Apr 2023 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Apr 2022 — Jun 2022 [monthly]
Not Yet Recruiting PHASE1
-
Feb 2022 — Apr 2022 [monthly]
Not Yet Recruiting PHASE1
-
Oct 2021 — Feb 2022 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- National Institute of Allergy and Infectious Diseases (NIAID)
For direct contact, visit the study record on ClinicalTrials.gov .